Previous close | 9.31 |
Open | 9.21 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 9.00 - 9.22 |
52-week range | 8.98 - 16.71 |
Volume | |
Avg. volume | 2,561 |
Market cap | 618.417M |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of May: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, New York, May 20, 2024Michael Levitan, VP Investor Relations and Corporate Communications will present on Monday, May 20 at 09:30 EDT/15:30 CET. For more information about this conference, or to schedule a
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.Leiden, the Netherlands, 15 May 2024: Pharming G
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Overall cash and marketable securitie